Onkologie. 2020:14(6):258-261 | DOI: 10.36290/xon.2020.089

Treatment of metastatic colorectal cancer in the year 2020

Lenka Ostřížková
Interní hematologická a onkologická klinika, FN Brno

Colorectal cancer is a major public health problem not only in the Czech Republic. In approximately 25 % of cases, distant metastases are diagnosed synchronously with a primary tumour of the colon or rectum. In about half of the patients, metastases occur metachronously. Patients in whom surgical treatment of metastases is feasible have the best prognosis for long-term survival in clinical stage IV. Unfortunately, in the large majority, the goal of treatment of metastatic colorectal cancer is to slow down disease progression and prolong survival with a good quality of life. Interdisciplinary cooperation and individual approach with respect to predictive and prognostic markers are the mainstay of modern treatment for colorectal cancer in the year 2020.

Keywords: colorectal cancer, predictive and prognostic markers, interdisciplinary approach.

Published: January 8, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ostřížková L. Treatment of metastatic colorectal cancer in the year 2020. Onkologie. 2020;14(6):258-261. doi: 10.36290/xon.2020.089.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zdravotnictví ČR: Nová data Národního onkologického registru ČR (NOR) za rok 2017 NZIS Report č. R/1 (09/2017) dostupné z www.uzis.cz/system/fi les/NZIS_REPORT_c_ R01_09_16_NOR_0.pdf.
    2. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-32. Go to original source... Go to PubMed...
    3. Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 2007; 14: 786-794. Go to original source... Go to PubMed...
    4. Minami Y, Kudo M. Radiofrequency ablation of liver metastases from colorectal cancer: a literature review. Gut Liver 2013; 7(1): 1-6. doi: 10.5009/gnl.2013.7.1.1. Go to original source... Go to PubMed...
    5. Oshowo A, Gillams A, Harrison E et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003; 90(10): 1240-1243. doi: 10.1002/bjs.4264. Go to original source... Go to PubMed...
    6. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27(8): 1386-1422. doi: 10.1093/annonc/mdw235. Go to original source... Go to PubMed...
    7. Lykoudis PM, O'Reilly, Nastos K, et al. Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg 2014; 101: 605-612. Go to original source... Go to PubMed...
    8. Broquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronnous colorectal liver metastases in 156 consecutive patients: classis, combined or revesed strategy? J Am Coll Surg 2010; 210: 934-941. Go to original source... Go to PubMed...
    9. Khattak MA, Martin H, Davidson A, et al. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin Colorectal Cancer 2015; 14 (2): 81-90. doi: 10.1016/j.clcc.2014.12. 011. Go to original source... Go to PubMed...
    10. Tran B, Kopetz S, tie J, et al. Impact of B RAF mutation and microsatellite instability on metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-4632. Go to original source... Go to PubMed...
    11. Vanderwalde A, Spetzler D, Xiao N, et a. Evaluation of microsatelite instability assesment by usingtargeted next-generation sequencing and compared with PD-L1 and tumor mutational bunder in 11,348 patients. Cancer med. 2018; 7: 746-756. Go to original source... Go to PubMed...
    12. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value primary tumour side in pacients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017; 28: 1713-1729. Go to original source... Go to PubMed...
    13. Andre T, Shiu KK, Won Kim T, Vittrup Jensen B, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. Journal of Clinical Oncology (IF 32.956) Pub Date: 2020-06-01, DOI: 10.1200/jco.2020.38.18_suppl.lba4.Další literatura u autorky a na www.onkologiecs.cz Go to original source...
    14. Zhu D, Zhong Y, Wei Y, et al. Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. PLoS One 2014; 9(1): e86543. doi: 10.1371/journal.pone.0086543 Go to original source... Go to PubMed...
    15. Bonney GK, Coldham C, Adam R, et al. Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; an international multi-center data analysis using LiverMetSurvey. J Surg Oncol 2015; 111(6): 716-724. doi: 10.1002/jso.23899. Go to original source... Go to PubMed...
    16. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22 (2): 229-237. doi: 10.1200/JCO.2004.05.113. Go to original source... Go to PubMed...
    17. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26 (12): 2013-2019. doi: 10.1200/JCO.2007.14.9930. Go to original source... Go to PubMed...
    18. Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371 (17): 1609-1618. doi: 10.1056/NEJMoa 1403108. Go to original source... Go to PubMed...
    19. Venook AP, Niedzwiecki D, Lenz HJ, et al. CALB /SWOG 80405:Phase III trial of irinothecan/5FU/leucovorin (FOLFIRI) or oxaliplatin /5FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patient with K RAS wild type untreted metastatic adenocarcinoma of the colo nor re J. Clin Oncol 2014; 32(15suppl): LBA3. Go to original source...
    20. Heineman V, Weikersthal LF Von, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI+ bevacizumab as first line treatment for patients with metastatic colorectal cancer (FIRE3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10): 1065-1075. doi: 10.16/S1470-2045(14)703304. Go to original source...
    21. Douillard J, Siena S, Tabernero J, et al. Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). J Clin Oncol 2013; 31(Suppl): abstr 3620. Go to original source... Go to PubMed...
    22. Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 2017 Apr 19, doi: 10.1007/s00384-017-2800-1. Go to original source... Go to PubMed...
    23. Geissler M, Martens UM, Knorrenschield R, et al. mFOLFOXIRI 1 panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109) Ann Oncol. 2017; 28(suppl 5): Abstr 583P. Go to original source...
    24. Benavides M, Carrato A, Abad A, et al. Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group. Ann Oncol. 2017; 28(suppl 5): Abstr 4750. Go to original source...
    25. Holch JW, Stintzing S, Held S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Kullmann F, Scheithauer W, Kirchner T, von Einem JC, Modest DP, Heinemann V. Right-sided colorectal cancer (RC): response to frst-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR) J Clin Oncol. 2017; 35(Suppl): 3586. doi: 10.1200/JCO.2017.35.15_suppl.3586. Go to original source...
    26. Douillard JY, Salvatore S, Tabernero J, et al. Overall survival (OS) and tumor shrinkage outcomes in partients with symp tomatic/asymp tomatic mCRC: data from the PRIME study. Ann Oncol 2013; 24(Suppl 4): iv, 32-iv33. Go to original source...
    27. Heinemann V, Modest D, Fischer von Weikersthal L, et al. Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306). Ann Oncol 2014; 25(Suppl 2): abstr. O-0030. Go to original source...
    28. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomized phase 3 trial. Lancet Oncol, 2013; 14: 29-37. Go to original source... Go to PubMed...
    29. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol, 2012; 30: 3499-3506. Go to original source... Go to PubMed...
    30. Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, et al. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer DOI: 10.1200/JCO.18.02459 Journal of Clinical Oncology 37, no. 17 (June 10, 2019) 1460-1469. Go to original source... Go to PubMed...
    31. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refraktory metastatic colorectal cancer. N Engl J Med 2015; 372: 1909-1919. Go to original source... Go to PubMed...
    32. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treared metastatic colorectal cancer (CORRECT): an international, multicentre, rendomised,placebo-controlled, phase III, Trial Lancet 2013; 381: 303-312. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.